Abstract:Background The medical therapy of prostatic symptoms (MTOPS) trial randomized men with symptoms of benign prostatic hyperplasia (BPH) and followed response of treatment with a 5α‐reductase inhibitor (5ARI), an alpha‐adrenergic receptor antagonist (α‐blocker), the combination of 5ARI and α‐blocker or no medical therapy (none). Medical therapy reduced risk of clinical progression by 66% but the reasons for nonresponse or loss of therapeutic response in some patients remains unresolved. Our previous work showed that prostatic glucocorticoid levels are increased in 5ARI‐treated patients and that glucocorticoids can increased branching of prostate epithelia in vitro. To understand the transcriptomic changes associated with 5ARI treatment, we performed bulk RNA sequencing of BPH and control samples from patients who received 5ARI versus those that did not. Deconvolution analysis was performed to estimate cellular composition. Bulk RNA sequencing was also performed on control versus glucocorticoid‐treated prostate epithelia in 3D culture to determine underlying transcriptomic changes associated with branching morphogenesis. Method Surgical BPH (S‐BPH) tissue was defined as benign prostatic tissue collected from the transition zone (TZ) of patients who failed medical therapy while control tissue termed Incidental BPH (I‐BPH) was obtained from the TZ of men undergoing radical prostatectomy for low‐volume/grade prostatic adenocarcinoma confined to the peripheral zone. S‐BPH patients were divided into four subgroups: men on no medical therapy (none: n = 7), α‐blocker alone (n = 10), 5ARI alone (n = 6) or combination therapy (α‐blocker and 5ARI: n = 7). Control I‐BPH tissue was from men on no medical therapy (none: n = 8) or on α‐blocker (n = 6). A human prostatic cell line in 3D culture that buds and branches was used to identify genes involved in early prostatic growth. Snap‐frozen prostatic tissue taken at the time of surgery and 3D organoids were used for RNA‐seq analysis. Bulk RNAseq data were deconvoluted using CIBERSORTx. Differentially expressed genes (DEG) that were statistically significant among S‐BPH, I‐BPH, and during budding and branching of organoids were used for pathway analysis. Results Transcriptomic analysis between S‐BPH (n = 30) and I‐BPH (n = 14) using a twofold cutoff (p

Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5‐alpha reductase inhibitor resistance